{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:11:41Z","timestamp":1788793901223,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jdermsci.2026.07.006","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:42:24Z","timestamp":1783921344000},"page":"108-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inflammaging in melanoma: Precision control for optimizing immune checkpoint inhibition"],"prefix":"10.1016","volume":"123","author":[{"given":"Hisashi","family":"Kanemaru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Luong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumito","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdermsci.2026.07.006_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"issue":"15","key":"10.1016\/j.jdermsci.2026.07.006_bib2","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1016\/j.cell.2024.05.026","article-title":"Correction of age-associated defects in dendritic cells enables CD4+ T cells to eradicate tumors","volume":"187","author":"Zhivaki","year":"2024","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.jdermsci.2026.07.006_bib3","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41574-018-0059-4","article-title":"Inflammaging: a new immune-metabolic viewpoint for age-related diseases","volume":"14","author":"Franceschi","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.jdermsci.2026.07.006_bib4","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3389\/fimmu.2017.01960","article-title":"Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes?","volume":"8","author":"Fulop","year":"2017","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jdermsci.2026.07.006_bib5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12272-024-01529-7","article-title":"Immunosenescence and age-related immune cells: causes of age-related diseases","volume":"48","author":"Kim","year":"2025","journal-title":"Arch. Pharm. Res."},{"issue":"12","key":"10.1016\/j.jdermsci.2026.07.006_bib6","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.jdermsci.2026.07.006_bib7","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/s43587-025-00888-0","article-title":"Nonuniversality of inflammaging across human populations","volume":"5","author":"Franck","year":"2025","journal-title":"Nat. Aging"},{"issue":"2","key":"10.1016\/j.jdermsci.2026.07.006_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12016-021-08909-7","article-title":"Immunosenescence, inflammaging, and frailty: role of myeloid cells in age-related diseases","volume":"64","author":"Bleve","year":"2023","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"6","key":"10.1016\/j.jdermsci.2026.07.006_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"7203","key":"10.1016\/j.jdermsci.2026.07.006_bib10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jdermsci.2026.07.006_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.jdermsci.2026.07.006_bib12","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3389\/fonc.2019.01148","article-title":"Immune system evasion as hallmark of melanoma progression: the role of dendritic cells","volume":"9","author":"Tucci","year":"2019","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.jdermsci.2026.07.006_bib13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jdermsci.2026.07.006_bib14","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cell.2022.01.008","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"185","author":"Morad","year":"2022","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.jdermsci.2026.07.006_bib15","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy\u2013current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"26","key":"10.1016\/j.jdermsci.2026.07.006_bib16","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7528","key":"10.1016\/j.jdermsci.2026.07.006_bib17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jdermsci.2026.07.006_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103067","article-title":"A mechanism of cooling hot tumors: Lactate attenuates inflammation in dendritic cells","volume":"24","author":"Kanemaru","year":"2021","journal-title":"iScience"},{"issue":"12","key":"10.1016\/j.jdermsci.2026.07.006_bib19","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s43587-025-00984-1","article-title":"Cell populations in human breast cancers are molecularly and biologically distinct with age","volume":"5","author":"Parsons","year":"2025","journal-title":"Nat. Aging"},{"issue":"21","key":"10.1016\/j.jdermsci.2026.07.006_bib20","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1016\/j.cell.2024.08.013","article-title":"Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy","volume":"187","author":"Chhabra","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jdermsci.2026.07.006_bib21","article-title":"CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy","volume":"4","author":"Huseni","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"6371","key":"10.1016\/j.jdermsci.2026.07.006_bib22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jdermsci.2026.07.006_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/CMR.0b013e3283543d72","article-title":"Interleukin-6 and melanoma","volume":"22","author":"Hoejberg","year":"2012","journal-title":"Melanoma Res."},{"issue":"1","key":"10.1016\/j.jdermsci.2026.07.006_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.jdermsci.2026.07.006_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin. Immunol."},{"issue":"12","key":"10.1016\/j.jdermsci.2026.07.006_bib26","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s00262-017-2052-5","article-title":"Interleukin 6 induces M2 macrophage differentiation by STAT3 activation that correlates with gastric cancer progression","volume":"66","author":"Fu","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"10.1016\/j.jdermsci.2026.07.006_bib27","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/82763","article-title":"IL-6 switches the differentiation of monocytes from dendritic cells to macrophages","volume":"1","author":"Chomarat","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jdermsci.2026.07.006_bib28","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3389\/fonc.2019.01223","article-title":"IL-6 and IL-8 are linked with myeloid-derived suppressor cell accumulation and correlate with poor clinical outcomes in melanoma patients","volume":"9","author":"Tobin","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.jdermsci.2026.07.006_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/2326-6066.CIR-13-0030","article-title":"Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression","volume":"1","author":"Tsukamoto","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jdermsci.2026.07.006_bib30","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1038\/ncomms7702","article-title":"IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age","volume":"6","author":"Tsukamoto","year":"2015","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.jdermsci.2026.07.006_bib31","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-18-0118","article-title":"Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment","volume":"78","author":"Tsukamoto","year":"2018","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.jdermsci.2026.07.006_bib32","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell."},{"issue":"6","key":"10.1016\/j.jdermsci.2026.07.006_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006814","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa'ak","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.jdermsci.2026.07.006_bib34","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.4049\/jimmunol.2000523","article-title":"IL-1\u03b1 Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma","volume":"206","author":"Singh","year":"2021","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.jdermsci.2026.07.006_bib35","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1073\/pnas.0437939100","article-title":"IL-1 is required for tumor invasiveness and angiogenesis","volume":"100","author":"Voronov","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.jdermsci.2026.07.006_bib36","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","article-title":"Interleukin-1 and related cytokines in the regulation of inflammation and immunity","volume":"50","author":"Mantovani","year":"2019","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.jdermsci.2026.07.006_bib37","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/1078-0432.CCR-05-1603","article-title":"The role of interleukin 1 in growth and metastasis of human cancer xenografts","volume":"12","author":"Elaraj","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jdermsci.2026.07.006_bib38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jconrel.2007.07.015","article-title":"Sustained delivery of IL-1 Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases","volume":"123","author":"Lavi","year":"2007","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.jdermsci.2026.07.006_bib39","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1541-7786.MCR-11-0279","article-title":"Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma","volume":"9","author":"Qin","year":"2011","journal-title":"Mol. Cancer Res."},{"issue":"6720","key":"10.1016\/j.jdermsci.2026.07.006_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/science.adn0327","article-title":"Hematopoietic aging promotes cancer by fueling IL-1\u237a-driven emergency myelopoiesis","volume":"386","author":"Park","year":"2024","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.jdermsci.2026.07.006_bib41","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ccell.2021.04.011","article-title":"Interleukin-1 in tumor progression, therapy, and prevention","volume":"39","author":"Garlanda","year":"2021","journal-title":"Cancer Cell."},{"key":"10.1016\/j.jdermsci.2026.07.006_bib42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3389\/fcell.2020.00365","article-title":"The balance of TNF mediated pathways regulates inflammatory cell death signaling in healthy and diseased tissues","volume":"8","author":"Webster","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jdermsci.2026.07.006_bib43","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3389\/fimmu.2019.01818","article-title":"The TNF paradox in cancer progression and immunotherapy","volume":"10","author":"Montfort","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jdermsci.2026.07.006_bib44","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jdermsci.2026.07.006_bib45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdermsci.2016.12.019","article-title":"Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-\u03b1 is a biomarker of nivolumab recativity","volume":"86","author":"Tanaka","year":"2017","journal-title":"J. Dermatol. Sci."},{"issue":"3","key":"10.1016\/j.jdermsci.2026.07.006_bib46","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ijc.35416","article-title":"TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: results from the MELANF\u03b1 clinical study","volume":"157","author":"Virazels","year":"2025","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.jdermsci.2026.07.006_bib47","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","article-title":"Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial","volume":"27","author":"Montfort","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.jdermsci.2026.07.006_bib48","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.jdermsci.2026.07.006_bib49","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s11864-022-00948-2","article-title":"Promising blood-based biomarkers for melanoma: recent progress of liquid biopsy and its future perspectives","volume":"23","author":"Kanemaru","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.jdermsci.2026.07.006_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-75383-0","article-title":"Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy","author":"Kanemaru","year":"2026","journal-title":"Nat. Commun."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181126001234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181126001234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:00:44Z","timestamp":1788793244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181126001234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0923181126001234"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2026.07.006","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammaging in melanoma: Precision control for optimizing immune checkpoint inhibition","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2026.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}